

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab



Richard W. Joseph¹, Jeroen Elassaiss-Schaap², Richard Kefford^{3,4}, Wen-Jen Hwu⁵, Jedd D. Wolchok⁶, Anthony M. Joshua^{7,8}, Antoni Ribas⁹, F. Stephen Hodi¹⁰, Omid Hamid¹¹, Caroline Robert¹², Adil Daud¹³, Roxana Dronca¹⁴, Peter Hersey¹⁵, Jeffrey S. Weber¹⁶, Amita Patnaik¹⁷, Dinesh P. de Alwis¹⁸, Andrea Perrone¹⁸, Jin Zhang¹⁹, S. Peter Kang¹⁸, Scot Ebbinghaus¹⁸, Keaven M. Anderson¹⁹, and Tara C. Gangadhar²⁰

Abstract

Purpose: The purpose of this study was to assess the association of baseline tumor size (BTS) with other baseline clinical factors and outcomes in pembrolizumab-treated patients with advanced melanoma in KEYNOTE-001 (NCT01295827).

Experimental Design: BTS was quantified by adding the sum of the longest dimensions of all measurable baseline target lesions. BTS as a dichotomous and continuous variable was evaluated with other baseline factors using logistic regression for objective response rate (ORR) and Cox regression for overall survival (OS). Nominal *P* values with no multiplicity adjustment describe the strength of observed associations.

Results: Per central review by RECIST v1.1, 583 of 655 patients had baseline measurable disease and were included in this *post hoc* analysis. Median BTS was 10.2 cm (range, 1–89.5). Larger median BTS was associated with Eastern

Cooperative Oncology Group performance status 1, elevated lactate dehydrogenase (LDH), stage M1c disease, and liver metastases (with or without any other sites; all $P \leq 0.001$). In univariate analyses, BTS below the median was associated with higher ORR (44% vs. 23%; $P < 0.001$) and improved OS (HR, 0.38; $P < 0.001$). In multivariate analyses, BTS below the median remained an independent prognostic marker of OS ($P < 0.001$) but not ORR. In 459 patients with available tumor programmed death ligand 1 (PD-L1) expression, BTS below the median and PD-L1–positive tumors were independently associated with higher ORR and longer OS.

Conclusions: BTS is associated with many other baseline clinical factors but is also independently prognostic of survival in pembrolizumab-treated patients with advanced melanoma. *Clin Cancer Res*; 24(20); 4960–7. ©2018 AACR.

See related commentary by Warner and Postow, p. 4915

Introduction

There are multiple clinical factors associated with the overall prognosis for patients with metastatic melanoma including

Eastern Cooperative Oncology Group performance status (ECOG PS), metastasis (M) stage as defined by the American Joint Committee on Cancer, and serum levels of lactate

¹Department of Medical Oncology, Mayo Clinic, Jacksonville, Florida. ²PD-value, Pharmacometrics, Utrecht, the Netherlands. ³Department of Clinical Medicine, Macquarie University, Sydney, Australia. ⁴Department of Clinical Medicine, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia, Sydney, Australia. ⁵Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. ⁶Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ⁷Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. ⁸Department of Medical Oncology, Kinghorn Cancer Centre, Sydney, Australia. ⁹Department of Medicine, University of California, Los Angeles, Los Angeles, California. ¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ¹¹Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, California. ¹²Gustave Roussy and Paris-Sud University, Service de Dermatologie, Villejuif, France. ¹³Department of Hematology/Oncology, University of California, San Francisco, San Francisco, California. ¹⁴Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota. ¹⁵Department of Medical Oncology, University of Sydney, Sydney, Australia. ¹⁶Department of Medicine, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York. ¹⁷Department of Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio, Texas. ¹⁸Department of Oncology Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey. ¹⁹Department of Biostatistics and Research Decision Sciences, Merck &

Co., Inc., Kenilworth, New Jersey. ²⁰Department of Medicine, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Corrected online October 16, 2018.

R.W. Joseph and J. Elassaiss-Schaap contributed equally to this article.

Prior Presentation (full or in part):

50th Annual Meeting of the American Society of Clinical Oncology, May 30–June 3, 2014.

Eleventh International Congress of the Society for Melanoma Research, November 13–17, 2014.

Corresponding Author: Richard W. Joseph, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224. Phone: 904-953-7290; fax: 904-953-6801; E-mail: joseph.richard@mayo.edu

doi: 10.1158/1078-0432.CCR-17-2386

©2018 American Association for Cancer Research.

Translational Relevance

Although increased tumor burden is thought to be associated with worse outcomes in patients with metastatic melanoma, there is a lack of data to quantify the impact of tumor burden on patient outcomes. Herein, we quantify baseline tumor size in a large cohort of patients who underwent treatment with the immunotherapy pembrolizumab. We identified baseline tumor size to be an independent marker of prognosis in this cohort of patients. If validated, we hypothesize that baseline tumor size could be a factor to stratify patients in future clinical studies.

dehydrogenase (LDH; refs. 1–4). Medical oncologists often use these prognostic factors to risk-stratify their patients, which may influence treatment decisions.

In addition to the above-listed prognostic factors, clinicians commonly take into consideration an assessment of a patient's tumor burden or baseline tumor size (BTS) when making treatment decisions. For patients with a high burden of disease, a more aggressive treatment approach could be considered, and conversely for those with a lower tumor burden, a less aggressive approach could be considered. Despite the common use of BTS in clinical decision-making, there is a relative lack of data on both defining tumor burden and evaluating the impact of tumor burden on outcome with therapy.

The purpose of this study was to retrospectively assess the impact of BTS on clinical outcomes in patients with metastatic melanoma treated with the anti-programmed death 1 (PD-1) antibody pembrolizumab in the KEYNOTE-001 trial (ClinicalTrials.gov identifier, NCT01295827). Specifically, we assessed the relationship between BTS and several traditional clinical prognostic factors specific to melanoma (e.g., LDH and M-stage) as well as other baseline characteristics such as age, gender, ECOG PS, BRAF status, previous treatments, tumor expression of programmed death ligand 1 (PD-L1), and site of metastases. In addition, we assessed the association of BTS with the clinical outcomes of objective response rate (ORR) and overall survival (OS). We hypothesized that patients with lower BTS would have lower risk clinical factors as well as improved clinical outcomes when compared with patients with larger BTS or nonpulmonary metastases.

Materials and Methods

Patient selection and treatment

As described previously (5–10), patients with advanced melanoma regardless of prior treatment, ECOG PS 0 to 1, ≥ 1 measurable lesion per investigator assessment, and normal organ function were eligible for the KEYNOTE-001 trial. Only patients with measurable disease at baseline, as assessed by central review and defined by RECIST v1.1 (11) were included in this analysis. Patients received pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks. In randomized comparisons, these dosages have shown comparable efficacy (6, 8, 10, 12, 13).

The study protocol was approved by the appropriate Institutional Review Boards at each participating institution. The study was conducted in accordance with the protocol, good clinical

practice guidelines, the provisions of the Declaration of Helsinki, and all local regulations. All patients provided written informed consent.

Assessments

BTS was quantified by adding the sum of the longest dimensions of all measurable baseline target lesions as provided by central radiology review and assessed per RECIST v1.1 modified to include a maximum of 10 target lesions in total if clinically relevant or five per organ. We used 10 lesions instead of 5, as per RECIST v1.1, because at the time of the current study, anti-PD-1 therapy was in the early stages of development, and the best way to monitor for response was unclear. In the current study, we used all 10 lesions (in patients who had 10 lesions) per the design of the study. Best overall response by blinded independent central review per RECIST v1.1 was categorized as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Analyses were performed using the best response by week 28. ORR was defined as the percentage of patients who achieved CR or PR; disease control rate (DCR) was defined as the percentage of patients who achieved CR, PR, or SD; and OS was defined as time from enrollment to death from any cause.

Tumor PD-L1 expression was assessed by a prototype IHC assay (QualTek Molecular Laboratories; ref. 14) in pretreatment tumor biopsy samples using the 22C3 antibody (Merck & Co., Inc.). PD-L1 positivity was defined as membranous staining in $\geq 1\%$ of tumor and/or immune cells in tumor nests.

Statistical analysis

BTS was compared in subgroups defined by traditional baseline clinical factors [ECOG PS (0 vs. 1), LDH level (normal vs. elevated), M stage (M0, M1a, or M1b vs. M1c), age (below vs. above the median), and sex (male vs. female)], as well as with other baseline clinical factors [*BRAF*^{V600} mutation status (mutant vs. wild type), prior brain metastases (yes vs. no), prior ipilimumab treatment (naïve vs. exposed), number of prior therapies (0 vs. ≥ 1), pembrolizumab dose and schedule (10 mg/kg every 2 weeks vs. 10 mg/kg every 3 weeks vs. 2 mg/kg every 3 weeks), tumor PD-L1 status (positive vs. negative), and site of metastasis (lung only vs. liver (with or without any other sites) vs. other)] using the nonparametric Kruskal–Wallis test. Baseline factors were analyzed for their association with ORR using logistic regression. Univariate factors with $P < 0.10$ were then analyzed using a multivariate logistic regression to test independence in a stepwise procedure with alpha-to-enter 0.025 and alpha-to-remove 0.05. The association of baseline clinical factors with OS was estimated with a univariate Cox proportional hazard analysis applying the Efron method for handling ties. Statistical analyses were done using SAS (version 9.3). The data cutoff date for this *post hoc* analysis was September 18, 2015.

Results

Patients and association of BTS with baseline clinical characteristics

Of the 655 patients with advanced melanoma treated in the KEYNOTE-001 trial, 583 had measurable disease at baseline by central RECIST v1.1 and were included in the analysis. Baseline characteristics for these patients are outlined in Table 1.

Table 1. Baseline patient and disease characteristics by baseline tumor size

Factor	N (% ^a)	BTS below median, n/N (%)	BTS above median, n/N (%)	P
Total	583 (100)	292/583 (50)	291/583 (50)	
Traditional factors				
ECOG PS				
0	387 (66)	224/387 (58)	163/387 (42)	<0.001
1	195 (34)	68/195 (35)	127/195 (65)	
LDH level				
Normal	333 (58)	226/333 (68)	107/333 (32)	<0.001
Elevated	238 (42)	63/238 (27)	175/238 (74)	
M stage				
M0, M1a, or M1b	119 (20)	96/119 (81)	23/119 (19)	<0.001
M1c	464 (80)	196/464 (42)	268/464 (58)	
Age				
Below median (≤61 years)	298 (51)	134/298 (45)	164/298 (55)	0.012
Above median (>61 years)	285 (49)	158/285 (55)	127/285 (45)	
Sex				
Male	365 (63)	179/365 (49)	186/365 (51)	0.514
Female	218 (37)	113/218 (52)	105/218 (48)	
Other factors				
<i>BRAF</i> ^{V600} mutation status				
Mutant	133 (23)	66/133 (50)	67/133 (50)	0.976
Wild type	444 (77)	221/444 (50)	223/444 (50)	
Prior brain metastases				
Yes	50 (9)	31/50 (62)	19/50 (38)	0.076
No	532 (91)	260/532 (49)	272/532 (51)	
Prior ipilimumab treatment				
Naïve	278 (48)	155/278 (56)	123/278 (44)	0.009
Exposed	305 (52)	137/305 (45)	168/305 (55)	
Number of prior therapies				
0	137 (23)	77/137 (56)	60/137 (44)	0.102
≥1	446 (77)	215/446 (48)	231/446 (52)	
Pembrolizumab dose and schedule				
10 mg/kg Q2W	168 (29)	92/168 (55)	76/168 (45)	0.329
10 mg/kg Q3W	272 (47)	133/272 (49)	139/272 (51)	
2 mg/kg Q3W	143 (25)	67/143 (47)	76/143 (53)	
Tumor PD-L1 status				
Positive	353 (77)	175/353 (50)	178/353 (50)	0.925
Negative	106 (23)	52/106 (49)	54/106 (51)	
Site of metastasis				
Lung only	84 (14)	74/84 (88)	10/84 (12)	<0.001
Liver, with or without any other sites	201 (34)	62/201 (31)	139/201 (69)	
Other	298 (51)	156/298 (52)	142/298 (48)	

Abbreviations: Q2W, every 2 weeks; Q3W, every 3 weeks.

^aPercentages calculated by using the number of patients with available data for each baseline characteristic as the denominator (may be <583 patients for some characteristics).

Median age was 61 years, and the majority had ECOG PS 0 (66%), normal LDH level (58%), and stage M1c disease (80%). Of the 23% of patients with *BRAF*^{V600}-mutant tumors, 68% had previously received a *BRAF* inhibitor. Most patients (77%) had previously received ≥1 therapy; 52% had previously received ipilimumab.

Median BTS was 10.2 cm (range, 1–89.5 cm; Supplementary Fig. S1). Several baseline clinical factors were associated with BTS. Larger median BTS was observed in patients with ECOG PS 1 compared with ECOG PS 0 (15.3 cm vs. 8.1 cm; $P < 0.001$), elevated LDH level compared with normal LDH level (17.3 cm vs. 6.2 cm; $P < 0.001$), stage M1c disease compared with other disease stages (13.1 cm vs. 4.3 cm; $P < 0.001$), and age below the median compared with age above the median (12.0 cm vs. 8.8 cm; $P = 0.038$). The location of metastases was also strongly associated with BTS. Patients with liver metastases (with or without any other sites) had larger median BTS versus those with lung only or other metastases (15.3 cm vs. 3.9 cm vs. 9.3 cm; $P < 0.001$). Compared with patients who were treatment naïve, patients with previously treated disease had larger median BTS (11.1 cm vs. 9.3 cm; $P =$

0.013), including those who previously received ipilimumab compared with those who were ipilimumab naïve (12.1 cm vs. 8.8 cm; $P = 0.002$).

Univariate analysis of baseline clinical factors associated with ORR

In the 583 patients with measurable disease at baseline, the CR rate was 10%, ORR was 33%, and DCR was 51% (Table 2). Several baseline clinical factors were associated with

Table 2. Summary of best overall response by independent review per RECIST v 1.1

	Total population, %	BTS below median, %	BTS above median, %	P
CR	10	18	2	<0.001
PR	24	26	21	0.149
SD	18	19	17	0.600
PD	39	33	45	0.005
ORR	33	44	23	<0.001
DCR	51	62	40	<0.001

Table 3. Univariate association of baseline patient and disease characteristics with survival and response

Factor	OS			Response	
	Alive at 1 year, % (95% CI)	HR	P	ORR, %	P
Traditional factors					
ECOG PS					
0	70 (65.6–74.7)	0.56	<0.001	36	0.100
1	51 (43.6–57.7)			29	
LDH level		0.37	<0.001		<0.001
Normal	79 (74.0–82.8)			43	
Elevated	44 (37.2–49.8)	21			
M stage		0.40	<0.001		<0.001
M0, M1a, or M1b	86 (78.6–91.4)			50	
M1c	58 (53.6–62.6)	29			
Age		0.93	0.534		0.464
Below median (≤ 61 years)	63 (56.7–67.8)			32	
Above median (> 61 years)	65 (59.6–70.6)	35			
Sex		0.91	0.400		0.180
Male	64 (58.5–68.4)			36	
Female	64 (57.6–70.4)	30			
Other factors					
<i>BRAF</i> ^{V600} mutation status		0.82	0.113		0.036
Wild type	66 (60.8–69.7)			36	
Mutant	59 (50.4–67.2)	26			
Prior brain metastases		0.84	0.391		1.000
Yes	68 (53.2–79.0)			34	
No	64 (59.2–67.4)	34			
Prior ipilimumab treatment		0.88	0.234		0.028
Naïve	68 (62.4–73.5)			38	
Exposed	60 (54.2–65.2)	29			
Number of prior therapies		0.77	0.053		0.009
0	70 (61.8–77.3)			43	
≥ 1	62 (57.3–66.3)	31			
Pembrolizumab dose and schedule		0.97	0.704		0.522
10 mg/kg Q2W	63 (55.5–70.1)			37	
10 mg/kg Q3W	64 (57.6–69.1)			32	
2 mg/kg Q3W	65 (56.8–72.5)	32			
BTS (SLD)		0.38	<0.001		<0.001
Below median (≤ 10.2 cm)	80 (74.6–83.9)			44	
Above median (> 10.2 cm)	48 (42.0–53.6)	23			
Tumor PD-L1 status		0.51	<0.001		<0.001
Positive	69 (63.6–73.4)			39	
Negative	45 (35.4–54.4)	13			
Site of metastasis		0.29	<0.001		<0.001
Lung only	89 (80.4–94.3)			62	
Liver, with or without any other sites	53 (46.2–60.1)			22	
Other	64 (58–68.9)	0.65		33	

Abbreviations: CI, confidence interval; Q2W, every 2 weeks; Q3W, every 3 weeks; SLD, sum of the longest diameters.

higher ORR, including normal LDH level compared with elevated LDH level ($P < 0.001$), stage M0, M1a, or M1b disease compared with M1c disease ($P < 0.001$), *BRAF*^{V600} wild-type status compared with *BRAF*^{V600}-mutant status ($P = 0.036$), no prior ipilimumab treatment compared with prior ipilimumab treatment ($P = 0.028$), no prior therapy compared with prior therapy ($P = 0.009$), BTS below the median compared with BTS above the median ($P < 0.001$), PD-L1–positive tumors compared with PD-L1–negative tumors ($P < 0.001$), and lung only metastases compared with liver (with or without any other sites) and other metastases ($P < 0.001$; Table 3). Patients with a BTS below the median were more likely to achieve CR (18% vs. 2%; $P < 0.001$) and had a higher ORR (44% vs. 23%; $P < 0.001$) and DCR (62% vs. 40%; $P < 0.001$) than patients with a BTS above the median (Table 2). Patients with lung only metastases experienced an ORR of 62%, whereas patients with liver metastases (with or without any other sites) had an ORR of 22%.

Univariate analysis of baseline clinical factors associated with OS

With a median follow-up of 32 months (range, 24–46 months), median OS was 24 months at the time of analysis. Of the 655 patients treated in the trial, 66% were alive at 1 year, 50% were alive at 2 years, and 40% were alive at 3 years.

Several baseline clinical factors were associated with improved OS, including ECOG PS 0 compared with 1 (HR, 0.56; $P < 0.001$), normal LDH level compared with elevated LDH level (HR, 0.37; $P < 0.001$), stage M0, M1a, or M1b disease compared with M1c disease (HR, 0.40; $P < 0.001$), no prior therapy compared with prior therapy (HR, 0.77; $P = 0.053$), BTS below the median compared with BTS above the median (HR, 0.38; $P < 0.001$), PD-L1–positive tumors compared with PD-L1–negative tumors (HR, 0.51; $P < 0.001$), and lung only and other metastases compared with liver metastases (with or without any other sites; HRs, 0.29, 0.65, and 1.00; $P < 0.001$; Table 3). Patients with lung only metastases had a 1-year




Figure 1. Relationship between baseline tumor size and survival. **A**, Kaplan-Meier estimate of OS. **B**, Baseline tumor size as a continuous effect on OS. CI, confidence interval.

OS rate of 89%, whereas patients with liver metastases (with or without any other sites) had a 1-year OS rate of 53%.

At 1 year, 80% of patients with BTS below the median were alive, compared with 48% of patients with BTS above the median ($P < 0.0001$; Fig. 1A). A continuous and direct relationship between BTS and risk for death was observed when BTS was assessed as a continuous variable (Fig. 1B). Using the median BTS of 10.2 cm as a comparator (HR, 1), a patient with BTS 30 cm had an HR for death of 2.36. Conversely, a patient with BTS 3.3 cm had an HR for death of 0.65.

Multivariate analysis of baseline clinical factors associated with ORR and OS

Among the eight factors associated with ORR in the univariate model, three remained independently associated with higher ORR in a multivariate model: normal LDH level (OR, 2.52; $P < 0.001$), no prior therapies (OR, 1.76; $P = 0.010$), and site of metastasis (ORs, 4.51 and 1.81; $P < 0.001$; Table 4). Of the 324 total deaths that occurred among treated patients with measurable disease at baseline, 315 occurred among the population included in the multivariate analysis. Among the seven factors associated with OS in the univariate model, four remained

Table 4. Independent factors on ORR

Factors	OR	P
Normal LDH level	2.52	<0.001
No prior therapies	1.76	0.010
Site of metastasis		<0.001
Lung only vs. liver, with or without any other sites	4.51	
Other vs. liver, with or without any other sites	1.81	

independently associated with longer OS in a multivariate model: normal LDH level (HR, 0.48; $P < 0.001$), BTS below the median (HR, 0.61; $P < 0.001$), ECOG PS of 0 (HR, 0.71; $P = 0.004$), and site of metastasis (HRs, 0.49 and 0.71; $P = 0.002$; Table 5).

Analysis of PD-L1 expression as a biomarker of ORR and OS

Of the 583 patients included in the analysis, 459 (79%) had tumor samples evaluable for PD-L1 expression, of which 353 (77%) had PD-L1-positive tumors and 106 (23%) had PD-L1-negative tumors (Table 1). Tumor PD-L1 expression was not associated with any baseline clinical factors except for prior ipilimumab treatment and site of metastasis because patients previously treated with ipilimumab were more likely to have PD-L1-positive tumors than those who were ipilimumab naïve (81% vs. 72%; $P = 0.015$), and patients with lung only metastases were more likely to have PD-L1-positive tumors than those with liver (with or without any other sites) or other sites of metastases (85% vs. 68% vs. 80%; $P = 0.008$). The percentage of patients with PD-L1-positive tumors did not differ among those with BTS above or below the median.

Patients with PD-L1-positive tumors were more likely to achieve an objective response than patients with PD-L1-negative tumors (39% vs. 13%; $P < 0.001$). After adjusting for other factors that were at least minimally associated with higher ORR ($P < 0.10$), normal LDH level (OR, 1.93; $P = 0.008$), no prior therapies (OR, 2.04; $P = 0.007$), BTS below the median (OR, 1.63; $P = 0.0496$), PD-L1-positive tumors (OR, 4.19; $P < 0.001$), and lung only or other metastasis (OR, 3.54 and 1.78; $P = 0.003$) remained independently associated with higher ORR.

In the 459 patients with tumor samples evaluable for PD-L1 expression, those with PD-L1-positive tumors were also more likely to be alive at 1 year than those with PD-L1-negative tumors (69% vs. 45%; $P < 0.001$; Supplementary Table S1). When these factors were combined in a multivariate model, six factors remained independently associated with longer OS: ECOG PS 0, normal LDH level, no prior therapies, BTS below the median, PD-L1-positive tumors, and lung metastases.

We also performed a subset analysis of the 139 treatment-naïve patients with measurable BTS (Supplementary Table S2; Supplementary Fig. S2). The median BTS in this subset was 10.2 cm; patients with BTS less than or equal to the median BTS were more likely to be alive at 1 year compared with those patients with a greater than median BTS (83% vs. 56%, $P < 0.001$), and median

Table 5. Independent factors on OS

Factors	HR	P
Normal LDH level	0.48	<0.001
BTS below median	0.61	<0.001
ECOG PS 0	0.71	0.004
Site of metastasis		0.002
Lung only vs. liver, with or without any other sites	0.49	
Other vs. liver, with or without any other sites	0.71	

survival was also significantly longer in patients with less than the median BTS (Supplementary Fig. S2). In terms of ORR, there was not a significant difference between patients above or below median BTS (50% vs. 38%, $P = 0.163$).

Discussion

To our knowledge, this is the first study to assess the prognostic effect of BTS on clinical outcomes in patients with metastatic melanoma treated with anti-PD-1 therapy. Not surprisingly, BTS was strongly associated with many baseline clinical factors and thus was also strongly associated with clinical outcomes. In our multivariate model, BTS was not independently associated with ORR but did remain independently associated with OS.

As BTS has not been routinely assessed and reported, it is difficult to contextualize the results of this work with previous studies that evaluated the effectiveness of immunotherapy in patients with metastatic melanoma. In previous studies of patients treated with high-dose IL2, higher ORR was associated with ECOG PS 0 (15), no prior systemic therapy (15) and decreased LDH level (16). In the current study of PD-1 blockade with pembrolizumab, higher ORR was associated with normal LDH level; stage M0, M1a, or M1b disease; *BRAF*^{V600} wild-type status; no prior ipilimumab treatment; no prior therapy; BTS below the median; PD-L1-positive tumors; and number of sites of metastases in a univariate analysis. In a multivariate analysis, only normal LDH level, no prior therapies, and number of sites of metastasis were independently associated with higher ORR. In the prospective phase III study that compared ipilimumab with glycoprotein 100, no pretreatment characteristics identified patients more likely to benefit from ipilimumab; however, BTS was not evaluated in that report (17). Others have used number of organ sites involved of greater than or less than 3 as an important marker of prognosis in patients with metastatic melanoma treated with dabrafenib and trametinib (18). As a part of future studies, we plan to incorporate number of involved organ sites as a potential surrogate for BTS.

Although this analysis cannot differentiate the predictive versus prognostic effect of baseline factors, we hypothesize that BTS represents a distinct balance between tumor antigen burden and the preexisting ineffective immune response that, when adequately augmented by PD-1 blockade, can result in an effective anti-tumor response. Huang and colleagues recently demonstrated that the magnitude of the pretreatment immune response is indeed related to tumor burden, suggesting an ineffective preexisting response; with PD-1 blockade, the increase in immune response relative to baseline tumor burden may be predictive of antitumor response (19). By this mechanism, BTS may be, in part, predictive of response to PD-1 blockade and prognostic of outcome as a result of both lead-time bias and a more efficient preexisting immune response.

Although patients with PD-L1-positive tumors had a higher ORR and better prognosis than patients with PD-L1-negative tumors, no association between BTS and PD-L1 expression was identified, that is, patients with a large BTS were as likely to have a PD-L1-positive tumor as patients with a small BTS. At present, PD-L1 expression remains a dynamic marker with unclear clinical usefulness in melanoma.

There are several potential clinical implications of this work. Our data suggest that there is a greater unmet medical need in patients with a larger BTS, a group that typically included

previously treated patients, which thereby supports use of PD-1 inhibitors earlier in the disease course. In support of earlier PD-1 blockade, the ORR for pembrolizumab in KEYNOTE-001 was 33% overall but was 45% in treatment-naïve patients (20). Other published data also suggest that ORR might be higher in previously untreated patients (13, 21). In addition, although patients with a larger BTS had decreased survival compared with those with a smaller BTS, the 1-year survival rate of 48% for patients with BTS above the median is clinically meaningful and indicates that patients still benefit from pembrolizumab despite having a large tumor burden. Finally, if BTS were validated in subsequent studies as a predictive factor, it might be additionally insightful to assess BTS, among other baseline factors, in randomized studies of dual checkpoint blockade versus single-agent PD-1 blockade as a step toward improving patient selection for combination therapy options that may have increased toxicity.

Our findings may also have implications for trial design in melanoma. Because of the strength of BTS as an independent prognostic factor, BTS could be considered a stratification factor for clinical trials of PD-1 blockade if validated in additional studies. However, the application of using BTS to stratify patients could be challenging because of the continuous relationship between BTS and risk for death; therefore, a validated cut-off point of BTS would be helpful in this respect. In addition, although cross-trial comparisons are challenging and never definitive, the prospective quantification of BTS could allow for assessment of similar patient populations when comparing trial designs.

In addition to BTS, well-known prognostic markers in melanoma, such as LDH level, ECOG PS, and M stage, were also strongly associated with clinical outcome in this study, supporting the applicability of these results to the general melanoma population. One of the more interesting findings of our analysis was the exceptionally good outcomes for patients with lung only metastases; these patients experienced a near tripling of ORR compared with patients with liver metastases (62% vs. 22%). Although independent validation of this finding is necessary, if confirmed, this information could aid in clinical decision making.

There are several important limitations of this work. First, our findings require prospective validation in an independent cohort. The effect of BTS on clinical outcomes in the KEYNOTE-002 (NCT01704287; ref. 12) and KEYNOTE-006 (NCT01866319; ref. 13) studies may help further address this question. Importantly, KEYNOTE-006 is a first-line study; therefore, it will be important to assess the value of BTS without the confounding element of prior treatment effect and to consider subsequent therapies in any analysis. Second, because the data derive from an uncontrolled study, conclusions cannot be drawn about whether BTS is prognostic or predictive in nature. Because BTS is associated with other known prognostic factors (such as elevated LDH and site of metastases), it is possible that it is a prognostic factor that might be associated with lower response across a variety of therapeutic categories. Another limitation is that there is no recognized gold standard to assess BTS. In this study, we evaluated the sum of the longest diameters of ≤ 10 target lesions and five lesions per organ, but we did not include lesions that are not captured by RECIST v1.1, such as bone lesions or lesions that did not meet RECIST v1.1 size criteria. We chose 10 lesions instead of 5, as per RECIST v1.1, because, at the time the study was designed, how to assess

response to anti-PD-1 agents was unclear. The design of the study included up to 10 lesions instead of the traditional 5 in RECIST v1.1 and, for the purposes of this article, we included all 10 lesions as captured in the database. Therefore, our assessment of BTS does not include all lesions present in the patient and does include up to 5 more lesions than would be counted in RECIST v1.1. Another limitation of the current study is that we did not explore the difference between having multiple small tumors and having one large tumor. We believe this work is important and should be a part of future of analyses in melanoma and other tumor types, along with analysis of the number of involved metastatic sites.

In summary, BTS is strongly associated with several baseline clinical factors and clinical outcomes in patients with metastatic melanoma treated with pembrolizumab. Because of the association of BTS with other known prognostic factors in melanoma, BTS should also be studied for its association with clinical outcomes of other antitumor agents. Because melanoma treatment strategies rapidly evolve, a key next step in advancing the field is to better define which therapy is best for the individual patient to minimize unnecessary toxicity without compromising clinical effectiveness. BTS may play a significant role in realizing individualized patient therapy.

Disclosure of Potential Conflicts of Interest

R.W. Joseph reports receiving commercial research grants from Merck and is a consultant/advisory board member for Bristol-Myers Squibb, Exelixis, Incyte, Insys, Merck, and Novartis. J. Ellassaiss-Schaap is an employee of Merck and holds ownership interest (including patents) in PD-value B.V. W.-J. Hwu reports receiving commercial research grants from Bristol-Myers Squibb, GlaxoSmithKline, MedImmune, and Merck and is a consultant/advisory board member for Array and Merck. J. D. Wolchok is a paid consultant at Bristol-Myers Squibb, Ono, Merck, MedImmune, Celgene, and Genentech, and receives research funding from Bristol-Myers Squibb, Merck, Genentech, and MedImmune. A. Ribas is a consultant/advisory board member for Merck. F.S. Hodi reports receiving commercial research grants from Bristol-Myers Squibb, holds ownership interest (including patents) in MICA-related disorders, and is a consultant/advisory board member for Amgen, Bristol-Myers Squibb, Celldex, EMD Serono, Genentech, Merck, and Novartis. O. Hamid reports receiving speakers bureau honoraria from Amgen, Bristol-Myers Squibb, Genentech, and Novartis and is a consultant/advisory board member for Amgen, Bristol-Myers Squibb, Merck, Novartis, and Roche. C. Robert is a consultant/advisory board member for Bristol-Myers Squibb, Merck, Novartis, Pierre Fabre, and Roche. A.I. Daud is a consultant/advisory board member for Bristol-Myers Squibb, Genentech, Merck, and Pulse. R.S. Dronca is a consultant/advisory board member for Elsevier Practice Update. J.S. Weber reports receiving speakers bureau honoraria from and is a consultant/advisory board member for Merck and is the shared owner of a patent with Biodesix. D.P. de Alwis is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. A. Perrone is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. J. Zhang is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. S.P. Kang is an employee and stockholder of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. S.W. Ebbinghaus is an employee of and holds ownership interest (including patents) in Merck. K. M. Anderson is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: R.W. Joseph, J. Ellassaiss-Schaap, W.-J. Hwu, C. Robert, A. Perrone, S.P. Kang, S. Ebbinghaus

Development of methodology: R.W. Joseph, O. Hamid, J. Zhang, S.P. Kang, K.M. Anderson

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): R.W. Joseph, R. Kefford, W.-J. Hwu, J.D. Wolchok, A.M. Joshua, A. Ribas, F.S. Hodi, O. Hamid, C. Robert, R. Dronca, P. Hersey, J.S. Weber, A. Patnaik

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): R.W. Joseph, J. Ellassaiss-Schaap, W.-J. Hwu, J.D. Wolchok, A.M. Joshua, A. Ribas, F.S. Hodi, O. Hamid, C. Robert, A. Daud, J.S. Weber, A. Patnaik, D.P. de Alwis, A. Perrone, J. Zhang, S.P. Kang, S. Ebbinghaus, K.M. Anderson

Writing, review, and/or revision of the manuscript: R.W. Joseph, J. Ellassaiss-Schaap, R. Kefford, W.-J. Hwu, J.D. Wolchok, A.M. Joshua, F.S. Hodi, O. Hamid, C. Robert, A. Daud, R. Dronca, J.S. Weber, D.P. de Alwis, A. Perrone, J. Zhang, S.P. Kang, S. Ebbinghaus, K.M. Anderson

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): R.W. Joseph, R. Kefford, O. Hamid, A. Daud
Study supervision: W.-J. Hwu, O. Hamid, J.S. Weber, A. Patnaik, S.P. Kang

Acknowledgments

The authors thank the patients and their families and caregivers, and all investigators and site personnel, for participating in the study; Roger Dansey,

MD (Merck & Co., Inc., Kenilworth, NJ), for critical manuscript review; and QualTek Molecular Laboratories (Goleta, CA) for PD-L1 IHC assay testing. Medical writing and editorial assistance, funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, were provided by Tricia Brown, MS, and Payal Gandhi, PhD, of the ApotheCom pembrolizumab team (Yardley, PA). Funding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 15, 2017; revised December 11, 2017; accepted April 17, 2018; published first April 23, 2018.

References

- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. *Am J Clin Oncol* 1982;5:649-55.
- Balch CM, Buzaid AC, Soong S-J, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. *J Clin Oncol* 2001;19:3635-48.
- Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, et al. LDH correlation with survival in advanced melanoma from two large, randomized trials (Oblimersen GM301 and EORTC 18951). *Eur J Cancer* 2009;45:1807-14.
- Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. *Cancer Invest* 2008;26:624-33.
- Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *N Engl J Med* 2013;369:134-44.
- Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. *Lancet* 2014;384:1109-17.
- Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Ellassaiss-Schaap J, Beeram M, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. *Clin Cancer Res* 2015;21:4286-93.
- Hamid O, Robert C, Ribas A, Wolchok F, Hodi S, Kefford R, et al. Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naïve (IPI-N) melanoma (MEL). *J Clin Oncol* 2014;32:abstr 3000.
- Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. *JAMA* 2016;315:1600-9.
- Robert C, Joshua AM, Weber JS, Ribas A, Hodi FS, Kefford RF, et al. Pembrolizumab (pembro; MK-3475) for advanced melanoma (MEL): randomized comparison of two dosing schedules. *Ann Oncol* 2014;25:1-41.
- Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. *AJR Am J Roentgenol* 2010;195:281-9.
- Ribas A, Puzanov I, Drummer R, Daud A, Schadendorf D, Robert C, et al. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. In: *Proceedings of The Society for Melanoma Research Eleventh International Congress*; 2014 Nov 13-17; Zurich, Switzerland. Clifton Park (NY): The Society for Melanoma Research; 2014.
- Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. *N Engl J Med* 2015;372:2521-32.
- Dolled-Filhart M, Locke D, Murphy T, Lynch F, Yearley JH, Frisman D, et al. Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue. *Arch Pathol Lab Med* 2016;140:1259-66.
- Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *J Clin Oncol* 1999;17:2105-16.
- Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. *J Immunother* 2012;35:66-72.
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711-23.
- Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomized trials. *Eur J Cancer* 2017;82:45-55.
- Huang AC, Postow MA, Orlovski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. *Nature* 2017;545:60-5.
- Daud A, Ribas A, Robert C, Hodi S, Wolchok JD, Joshua AM, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. *J Clin Oncol* 2015;33:abstr 9005.
- Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med* 2015;372:320-30.